Be the first person to write a business review for Pathwork Diagnostics, Inc.

PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada. PDL BioPharma, Inc. engages in the management of antibody humanization patents and royalty assets, which consist of its Queen et al. patents and license agreements with various biotechnology and pharmaceutical companies. The company licenses its technologies to make and sell antibodies that bind to respiratory syncytial virus, as well as antibodies that bind to the alpha subunit of the VLA-4 integrin. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006.

Peptimmune is pepped up about stopping the immune system when it malfunctions. The research-stage biotechnology company is focused on developing pharmaceuticals that treat medical conditions in which the body essentially attacks itself. Peptimmune conducts research and development programs on potential drug candidates targeting autoimmune and inflammatory ailments such as Crohn's disease, multiple sclerosis, and rheumatoid arthritis. The company partners with other pharmaceutical firms in some of its drug development efforts; it also relies on venture capital investors to help fund its research.

Perceptive Informatics understand that large clinical drug trials need more than little paper cups to dispense pills in. They also need massive information technology support to handle all of the data generated. As a subsidiary of contract research giant PAREXEL, Perceptive Informatics offers data capture and management systems for clinical trials conducted by large biotech and pharmaceutical companies. Its products are used to enroll and keep track of patients, organize trial results, and facilitate communication between participating doctors and trial organizers, as well as other services to speed the clinical-trial stage of drug development. It also manages medical imaging equipment and data for trials.

Peregrine Pharmaceuticals, Inc. company was founded in 1981 and is based in Tustin, California. Peregrine Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development and manufacture of monoclonal antibodies for the treatment of cancer and viral infections. The company develops clinical programs with its novel compounds bavituximab and Cotara, which are the clinical candidates under its anti-phosphatidylserine therapeutics and tumor necrosis therapy platforms. Its pipeline products comprise Bavituximab Plus Docetaxel, and Bavituximab plus carboplatin and paclitaxel, which are Phase II clinical trial products for treating advanced breast cancer patients; and Bavituximab plus carboplatin and paclitaxel, a Phase II clinical trial product for the treatment of non-small cell lung cancer, as well as Bavituximab, which is in Phase I monotherapy repeat dose safety study for treating solid tumor cancers, and in Phase Ib repeat dose safety study for the treatment of chronic hepatitis C virus infection co-infected with HIV. In addition, its pipeline products include Cotara, a product in Phase II, as well as a dosimetry and dose confirmation study for the treatment of glioblastoma multiforme, an aggressive form of brain cancer. Further, Peregrine, through its wholly owned subsidiary, Avid Bioservices, Inc., provides contract manufacturing services for biotechnology and biopharmaceutical companies, from pre-clinical drug supplies up through commercial-scale drug manufacture. Further, it provides services in support of Peregrine's product pipeline, including manufacture and scale-up of pre-clinical and clinical drug supplies.

Perlegen deciphers genetic signatures. The biotech research company performs whole genome scans to help drugmakers improve drug safety and efficacy and optimize clinical trials. The company also researches the genetic causes of disease and drug response. Using DNA probe arrays from Affymetrix, which owns some 20% of the firm, Perlegen examines multiple whole genomes at a time, looking for variations (single nucleotide polymorphisms, or SNPs) that are responsible for disease. SNPs and groups of SNPs, known as haplotypes, are also responsible for the response, or lack of one, to a drug. Drugmakers hope to use this information to develop genetically targeted medicines.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.